JP2018518465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518465A5 JP2018518465A5 JP2017557068A JP2017557068A JP2018518465A5 JP 2018518465 A5 JP2018518465 A5 JP 2018518465A5 JP 2017557068 A JP2017557068 A JP 2017557068A JP 2017557068 A JP2017557068 A JP 2017557068A JP 2018518465 A5 JP2018518465 A5 JP 2018518465A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- cells
- composition according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 210000003289 regulatory T cell Anatomy 0.000 claims description 11
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 5
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 230000004565 tumor cell growth Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 8
- 108090000695 Cytokines Proteins 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 2
- 230000003915 cell function Effects 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims 2
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100024263 CD160 antigen Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 1
- 102000001398 Granzyme Human genes 0.000 claims 1
- 108060005986 Granzyme Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100030704 Interleukin-21 Human genes 0.000 claims 1
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 1
- 102000004527 Interleukin-21 Receptors Human genes 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000024386 fungal infectious disease Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 108010046926 intraovarian peptides Proteins 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229930192851 perforin Natural products 0.000 claims 1
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021099845A JP7203904B2 (ja) | 2015-05-01 | 2021-06-16 | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155966P | 2015-05-01 | 2015-05-01 | |
| US62/155,966 | 2015-05-01 | ||
| US201562217419P | 2015-09-11 | 2015-09-11 | |
| US62/217,419 | 2015-09-11 | ||
| US201562237942P | 2015-10-06 | 2015-10-06 | |
| US62/237,942 | 2015-10-06 | ||
| PCT/US2016/026232 WO2016178779A1 (en) | 2015-05-01 | 2016-04-06 | Methods of mediating cytokine expression with anti ccr4 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021099845A Division JP7203904B2 (ja) | 2015-05-01 | 2021-06-16 | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518465A JP2018518465A (ja) | 2018-07-12 |
| JP2018518465A5 true JP2018518465A5 (enExample) | 2020-11-12 |
| JP6956639B2 JP6956639B2 (ja) | 2021-11-02 |
Family
ID=55795197
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557068A Active JP6956639B2 (ja) | 2015-05-01 | 2016-04-06 | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
| JP2021099845A Active JP7203904B2 (ja) | 2015-05-01 | 2021-06-16 | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021099845A Active JP7203904B2 (ja) | 2015-05-01 | 2021-06-16 | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10556956B2 (enExample) |
| EP (1) | EP3288977B1 (enExample) |
| JP (2) | JP6956639B2 (enExample) |
| KR (1) | KR20170138556A (enExample) |
| CN (1) | CN107849134B (enExample) |
| AU (1) | AU2016258742B9 (enExample) |
| CA (1) | CA2984608A1 (enExample) |
| NZ (1) | NZ736863A (enExample) |
| WO (1) | WO2016178779A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3130350A1 (en) * | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| EP3983447A4 (en) | 2019-06-14 | 2023-06-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against muc1 and methods of use thereof |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| WO2024141063A1 (zh) * | 2022-12-30 | 2024-07-04 | 甘李药业股份有限公司 | 抗rsv病毒抗体、组合物、制剂及其应用 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA152990A (en) | 1913-09-02 | 1914-01-06 | Percy W. Tooth | Rule pocket |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| HK1207655A1 (en) * | 2012-05-04 | 2016-02-05 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
| EP3699196A1 (en) | 2014-10-06 | 2020-08-26 | Dana Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
-
2016
- 2016-04-06 JP JP2017557068A patent/JP6956639B2/ja active Active
- 2016-04-06 KR KR1020177033937A patent/KR20170138556A/ko active Pending
- 2016-04-06 CN CN201680039232.5A patent/CN107849134B/zh active Active
- 2016-04-06 EP EP16717526.4A patent/EP3288977B1/en active Active
- 2016-04-06 US US15/571,202 patent/US10556956B2/en active Active
- 2016-04-06 AU AU2016258742A patent/AU2016258742B9/en active Active
- 2016-04-06 CA CA2984608A patent/CA2984608A1/en active Pending
- 2016-04-06 NZ NZ736863A patent/NZ736863A/en unknown
- 2016-04-06 WO PCT/US2016/026232 patent/WO2016178779A1/en not_active Ceased
-
2020
- 2020-02-10 US US16/786,798 patent/US11261256B2/en active Active
-
2021
- 2021-06-16 JP JP2021099845A patent/JP7203904B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koury et al. | Immunotherapies: exploiting the immune system for cancer treatment | |
| Huehls et al. | Bispecific T‐cell engagers for cancer immunotherapy | |
| JP2018518465A5 (enExample) | ||
| JP2020103301A5 (enExample) | ||
| JP7041439B2 (ja) | 固形がんの治療剤 | |
| CN109563170B (zh) | 抗gitr抗体及其用途 | |
| JP2020528750A (ja) | 抗ｃｔｌａ−４抗体およびその使用 | |
| JP2015527070A5 (enExample) | ||
| JP2022532490A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| JP2016525117A5 (enExample) | ||
| WO2020238926A1 (en) | Anti-b7-h3 antibodies | |
| Schlereth et al. | Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3 | |
| US12312409B2 (en) | Bispecific CD137-binding antibodies for T-cell activation | |
| US20250092127A1 (en) | IL-4/IL-13 Pathway Inhibitors for Enhanced Efficacy in Treating Cancer | |
| JP2021531813A (ja) | キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用 | |
| EP3883964A1 (en) | Bispecific antibody targeting transferrin receptor 1 and soluble antigen | |
| JP7566923B2 (ja) | 抗ｇｉｔｒ抗体およびその使用 | |
| CN117425492A (zh) | 双特异性t细胞接合剂的给药 | |
| Chen et al. | A trispecific T cell engager CD19xCD3xCD28 induces potent tumor-directed T cell activation and antitumor activity by simultaneously engagement of TCR and a co-stimulatory receptor CD28 | |
| CN116194142A (zh) | 通过施用pd-1抑制剂治疗癌症疼痛的方法 | |
| RU2020132497A (ru) | Связывающиеся с pd-1 антитела и способы их применения | |
| EA049485B1 (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака | |
| NZ769571A (en) | Antibodies binding pd-1 and uses thereof |